{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T17:50:53Z","timestamp":1773683453386,"version":"3.50.1"},"reference-count":54,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2000,5,10]]},"abstract":"<jats:p> PURPOSE: To ascertain the predictive value of Her-2\/neu overexpression and p53 mutations, assessed by immunohistochemistry, in high-risk primary breast cancer (HRPBC) treated with high-dose chemotherapy (HDCT). <\/jats:p><jats:p> PATIENTS AND METHODS: We obtained paraffin-embedded tumor blocks from 146 HRPBC patients previously enrolled at our program onto clinical trials of HDCT for four to nine involved axillary lymph nodes, \u2265 10 involved axillary nodes, or inflammatory carcinoma. All patients received the same HDCT regimen, with cyclophosphamide, cisplatin, and carmustine (STAMP-I), followed by autologous stem-cell transplantation. Median follow-up was 42 months (range, 5 to 90 months). The same pathologist, blinded to clinical outcome, reviewed all immunostained slides. <\/jats:p><jats:p> RESULTS: Positive results for Her-2\/neu and p53 were found in 44.5% and 34% of the patients, respectively. Positivity for Her-2\/neu was significantly associated with increased risk of relapse and death. No correlation was found between p53 mutations and relapse-free survival (RFS) or overall survival (OS). Multivariate analyses included Her-2\/neu overexpression and the following variables previously identified as independent predictors of outcome in this population: tumor size, nodal ratio (number of involved nodes\/number of dissected nodes), and hormone receptor status. All four variables had independent value. <\/jats:p><jats:p> CONCLUSION: Her-2\/neu overexpression is an independent negative predictor of RFS and OS in HRPBC treated with HDCT. Its inclusion in our previously described predictive model increases the predictive capacity of this model for the low-risk subgroup. In contrast, p53 mutations lack predictive value in this setting. <\/jats:p>","DOI":"10.1200\/jco.2000.18.10.2070","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T09:23:15Z","timestamp":1487928195000},"page":"2070-2080","source":"Crossref","is-referenced-by-count":45,"title":["Evaluation of the Predictive Value of Her-2\/neu Overexpression and p53 Mutations in High-Risk Primary Breast Cancer Patients Treated With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation"],"prefix":"10.1200","volume":"18","author":[{"given":"Yago","family":"Nieto","sequence":"first","affiliation":[{"name":"From the University of Colorado Bone Marrow Transplant Program and Departments of Pathology and BiostatisticsUniversity of Colorado, Denver, CO."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo J.","family":"Cagnoni","sequence":"additional","affiliation":[{"name":"From the University of Colorado Bone Marrow Transplant Program and Departments of Pathology and BiostatisticsUniversity of Colorado, Denver, CO."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samia","family":"Nawaz","sequence":"additional","affiliation":[{"name":"From the University of Colorado Bone Marrow Transplant Program and Departments of Pathology and BiostatisticsUniversity of Colorado, Denver, CO."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth J.","family":"Shpall","sequence":"additional","affiliation":[{"name":"From the University of Colorado Bone Marrow Transplant Program and Departments of Pathology and BiostatisticsUniversity of Colorado, Denver, CO."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronit","family":"Yerushalmi","sequence":"additional","affiliation":[{"name":"From the University of Colorado Bone Marrow Transplant Program and Departments of Pathology and BiostatisticsUniversity of Colorado, Denver, CO."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bret","family":"Cook","sequence":"additional","affiliation":[{"name":"From the University of Colorado Bone Marrow Transplant Program and Departments of Pathology and BiostatisticsUniversity of Colorado, Denver, CO."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peggy","family":"Russell","sequence":"additional","affiliation":[{"name":"From the University of Colorado Bone Marrow Transplant Program and Departments of Pathology and BiostatisticsUniversity of Colorado, Denver, CO."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"McDermit","sequence":"additional","affiliation":[{"name":"From the University of Colorado Bone Marrow Transplant Program and Departments of Pathology and BiostatisticsUniversity of Colorado, Denver, CO."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Murphy","sequence":"additional","affiliation":[{"name":"From the University of Colorado Bone Marrow Transplant Program and Departments of Pathology and BiostatisticsUniversity of Colorado, Denver, CO."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott I.","family":"Bearman","sequence":"additional","affiliation":[{"name":"From the University of Colorado Bone Marrow Transplant Program and Departments of Pathology and BiostatisticsUniversity of Colorado, Denver, CO."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy B.","family":"Jones","sequence":"additional","affiliation":[{"name":"From the University of Colorado Bone Marrow Transplant Program and Departments of Pathology and BiostatisticsUniversity of Colorado, Denver, CO."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R1-0276","doi-asserted-by":"crossref","unstructured":"Reese  DM,  Slamon  DJ:  HER-2\/ signal transduction in human breast and ovarian cancer.  Stem Cells 15:1,1997-8,  neu","DOI":"10.1002\/stem.150001"},{"key":"R2-0276","unstructured":"Mitchell  MS,  Press  MF:  The role of immunohistochemistry and fluorescence in situ hybridization for HER-2\/ in assessing the prognosis of breast cancer.  Semin Oncol 26:108,1999-116,  neu"},{"key":"R3-0276","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.18.1361"},{"key":"R4-0276","unstructured":"Ravdin  PM,  Green  S,  Albain  KS, et al:  Initial report of the SWOG biological correlative study of C-2 expression as a predictor of outcome in a trial comparing adjuvant CAF T with tamoxifen (T) alone.  Proc Am Soc Clin Oncol 17:97a,1998  (abstr 374)erbB"},{"key":"R5-0276","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199405053301802"},{"key":"R6-0276","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.18.1346"},{"key":"R7-0276","unstructured":"Seidman  AD,  Baselga  J,  Yao  T-J, et al:  Her-2\/ over-expression and clinical taxane sensitivity:  A multivariate analysis in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 15:104a,1996  (abstr 80)neu"},{"key":"R8-0276","unstructured":"Gianni  L,  Capri  G,  Mezzelani  A, et al:  HER-2\/ (HER2) amplification and response to doxorubicin\/paclitaxel (AT) in women with metastatic breast cancer.  Proc Am Soc Clin Oncol 16:139a,1997  (abstr 491)neu"},{"key":"R9-0276","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.9.3158"},{"key":"R10-0276","doi-asserted-by":"crossref","unstructured":"Elledge  RM,  Allred  DC:  Prognostic and predictive value of  and p21 in breast cancer.  Breast Cancer Res Treat 51:79,1998-98,  p53","DOI":"10.1023\/A:1006163101948"},{"key":"R11-0276","doi-asserted-by":"publisher","DOI":"10.1038\/nm0796-811"},{"key":"R12-0276","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/87.16.1254"},{"key":"R13-0276","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.1.121"},{"key":"R14-0276","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.5.1916"},{"key":"R15-0276","unstructured":"Peters  WP,  Berry  D,  Vredenburgh  JJ, et al:  Five year follow-up of high-dose combination alkylating agents with ABMT as consolidation after standard-dose CAF for primary breast cancer involving \u226510 axillary lymph nodes (Duke\/CALGB 8782).  Proc Am Soc Clin Oncol 14:317a,1995  (abstr 933)"},{"key":"R16-0276","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.6.2312"},{"key":"R17-0276","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701000"},{"key":"R18-0276","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.3.1000"},{"key":"R19-0276","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.5.1661"},{"key":"R20-0276","unstructured":"Peters  W,  Rosner  G,  Vredenburgh  J, et al:  A prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN):  Preliminary results of CALGB 9082\/SWOG 9114\/NCIC MA-13. Proc Am Soc Clin Oncol 18:1a,1999  (abstr 2)"},{"key":"R21-0276","unstructured":"The Scandinavian Breast Cancer Study Group 9401: Results from a randomized adjuvant breast cancer study with high dose chemotherapy with CTC supported by autologous bone marrow stem cells versus dose escalated and tailored FEC therapy.  Proc Am Soc Clin Oncol 18:2a,1999  (abstr 3)b"},{"key":"R22-0276","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.8.2882"},{"key":"R23-0276","unstructured":"Nieto  Y,  Cagnoni  PJ,  Xu  X, et al:  Predictive model for relapse after high-dose chemotherapy with peripheral blood progenitor cell support for high-risk primary breast cancer.  Clin Cancer Res 5:3425,1999-3431,"},{"key":"R24-0276","unstructured":"Press  MF,  Hung  G,  Godolphin  W, et al:  Sensitivity of HER-2\/ antibodies in archival tissue samples:  Potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 54:2771,1994-2777,  neu"},{"key":"R25-0276","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"R26-0276","doi-asserted-by":"publisher","DOI":"10.2307\/2344317"},{"key":"R27-0276","doi-asserted-by":"crossref","unstructured":"Cox  DR:  Regression models and life tables.  J R Stat Soc B 34:187,1972-220,","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"R28-0276","unstructured":"Haerslev  T,  Jacobsen  GK:  Microwave processing of formalin-fixed and paraffin-embedded sections improves the immunoreactivity of c-2 oncoprotein in breast carcinoma.  Appl Immunohistochem 1:223,1993-226,  erbB"},{"key":"R30-0276","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.2.462"},{"key":"R31-0276","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19991008)83:2<157::AID-IJC2>3.0.CO;2-L"},{"key":"R32-0276","doi-asserted-by":"publisher","DOI":"10.1016\/0046-8177(92)90032-X"},{"key":"R33-0276","doi-asserted-by":"publisher","DOI":"10.1002\/path.1711630205"},{"key":"R34-0276","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.7.1974"},{"key":"R35-0276","unstructured":"Bitran  JD,  Samuels  B,  Trujillo  Y, et al:  Her2\/ overexpression is associated with treatment failure in women with high-risk stage II and stage IIIA breast cancer (>10 involved lymph nodes) treated with high-dose chemotherapy and autologous hematopoietic progenitor cell support following standard-dose adjuvant therapy.  Clin Cancer Res 2:1509,1996-1513,  neu"},{"key":"R36-0276","unstructured":"Doroshow  JH,  Simpson  J,  Somlo  G, et al:  Immunohistochemical and histopathologic factors predicting progression-free survival (PFS) and overall survival (OS) following high-dose chemotherapy (HDCT) and stem cell rescue (SCR) for responsive metastatic breast cancer.  Proc Am Soc Clin Oncol 15:128a,1996  (abstr 176)"},{"key":"R37-0276","doi-asserted-by":"publisher","DOI":"10.1007\/s00282-999-0058-y"},{"key":"R38-0276","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.3.737"},{"key":"R39-0276","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.9.2639"},{"key":"R41-0276","unstructured":"Slamon  D,  Leyland-Jones  B,  Shak  S, et al:  Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+\/MBC) markedly increases anticancer activity:  A randomized, multinational controlled phase III trial. Proc Am Soc Clin Oncol 17:98a,1998  (abstr 377)"},{"key":"R42-0276","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0320(19970501)28:1<11::AID-CYTO2>3.0.CO;2-K"},{"key":"R43-0276","doi-asserted-by":"publisher","DOI":"10.1007\/BF00690187"},{"key":"R44-0276","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005824216444"},{"key":"R45-0276","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1996.6"},{"key":"R46-0276","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005993220824"},{"key":"R47-0276","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1994.164"},{"key":"R48-0276","unstructured":"Somlo  G,  Simpson  J,  Doroshow  J, et al:  Immunohistochemical (IH) expression of , estrogen (ER) and progesterone receptors (PR) and MIB-1 as well as increased mitotic index (MI) are predictors of outcome after high-dose chemotherapy (HDCT) and stem cell rescue (SCR) for high-risk breast cancer (HRBC) patients.  Proc Am Soc Clin Oncol 15:126a,1996  (abstr 170)p53"},{"key":"R49-0276","unstructured":"Brown  JM,  Wouters  BG:  Apoptosis, and tumor cell sensitivity to anticancer agents.  Cancer Res 59:1391,1999-1399,  p53"},{"key":"R50-0276","unstructured":"Han  JW,  Dionne  CA,  Kedersha  NL, et al:   status affects the rate of the onset but not the overall extent of doxorubicin-induced cell death in -1 fibroblasts constitutively expressing c-  Cancer Res 57:176,1997-182,  p53 rat Myc"},{"key":"R51-0276","unstructured":"Slichenmeyer  WJ,  Nelson  WG,  Slebos  RJ, et al:  Loss of a -associated G1 checkpoint does not decrease cell survival following DNA damage.  Cancer Res 53:4164,1993-4168,  p53"},{"key":"R52-0276","unstructured":"Fan  S,  Cherney  B,  Reinhold  W, et al:  Disruption of  function in immortalized human cells does not affect survival or apoptosis after taxol or vincristine treatment.  Clin Cancer Res 4:1047,1998-1054,  p53"},{"key":"R53-0276","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1201052"},{"key":"R54-0276","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.11.6163"},{"key":"R55-0276","doi-asserted-by":"publisher","DOI":"10.1172\/JCI6863"},{"key":"R56-0276","doi-asserted-by":"publisher","DOI":"10.1172\/JCI7861"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2000.18.10.2070","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T22:01:20Z","timestamp":1653516080000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2000.18.10.2070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,5,10]]},"references-count":54,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2000,5,10]]}},"alternative-id":["10.1200\/JCO.2000.18.10.2070"],"URL":"https:\/\/doi.org\/10.1200\/jco.2000.18.10.2070","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,5,10]]}}}